Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 13/20 | 0.37 |
| ▸ | CPT2 | P23786 | 11/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 6/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502393 | 1.00 | CPT1A (0.37) | CPT1ACPT2CPT1BAADATRIPK2 | |
| SCHEMBL23842132 | 0.91 | RIPK2 (0.35) | CPT1ACPT2CPT1BRIPK2XIAP | |
| SCHEMBL27204730 | 0.91 | RIPK2 (0.35) | CPT1ACPT2CPT1BRIPK2XIAP | |
| SCHEMBL21070364 | 0.91 | CPT1A (0.36) | CPT1ACPT2CPT1BRIPK2XIAP | |
| SCHEMBL21070360 | 0.91 | CPT1A (0.36) | CPT1ACPT2CPT1BRIPK2XIAP | |
| SCHEMBL26352158 | 0.90 | AADAT (0.38) | CPT1ACPT2CPT1BAADATRIPK2 | |
| SCHEMBL21071312 | 0.87 | ESR1 (0.37) | CPT1ACPT2CPT1BAADATRIPK2 | |
| SCHEMBL21071311 | 0.87 | ESR1 (0.37) | CPT1ACPT2CPT1BAADATRIPK2 | |
| SCHEMBL22818376 | 0.87 | ESR1 (0.37) | CPT1ACPT2CPT1BAADATRIPK2 | |
| SCHEMBL21071899 | 0.87 | ESR1 (0.37) | CPT1ACPT2CPT1BAADATRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CPT1A 4426/4885CPT2 4058/4885CPT1B 3778/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CPT1A 4426/4885CPT2 4058/4885CPT1B 3778/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CPT1A 4426/4885CPT2 4058/4885CPT1B 3778/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CPT1A 4426/4885CPT2 4058/4885CPT1B 3778/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CPT1A 4426/4885CPT2 4058/4885CPT1B 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.